ISSN 2410-7751 (Print)
ISSN 2410-776X (Online)
"Biotechnologia Acta" v. 6, No 4, 2013
https://doi.org/10.15407/biotech6.04.162
Р. 162-171, Bibliography 21, English
Universal Decimal classification: 578.27+615.32
Formerly Max-Planck-Institute for Medical Reseach,
Apl. Professor at Heidelberg University, Institute for Organic Chemistry, Germany
SCTL is the fully synthetic correlate of an enzymatic partially hydrolyzed extract from calf thymus. To exclude completely the transmission of bovine spongiformic encephalitis by the bovine thymus product a fully synthetic correlate of the active principles in the thymus tissue hydrolysate has been developed, namely SCTL. This synthetic peptide library has meanwhile substituted calf thymus extract preparations in several cosmetics and drug products. The active principles of SCTL have been invented by the author but the application of the drug substance in cosmetic and pharmaceutical products has been exploited by others. For SCTL only limited pharmacological and toxicological data are available. Some interesting biological activities, though, have been shown for SCTL which might explain to some extend the modes of action and its clinical effectiveness.
Key words: synthetic correlate of an enzymatic partially hydrolyzed extract from calf thymus.
© Palladin Institute of Biochemistry of National Academy of Sciences of Ukraine, 2013
References
1. Birr Chr., Stollenwerk U. Synthese von Thymosina1., einem Polypeptid des Thymus. Angew. Chem. 1979. P. 422–423; Angew. Chem., Int. Ed. Engl.18., 394–395 (1979).
2. Birr Chr., Ciardelli T.?L., Brodner O and Incefy, G.?S.: Small Peptides of Thymic Origin Stimulate T-Lymphocytes Subsets. Peptides (V.?Hruby and D. Rich, Eds.), Pierce Chem. Comp., Rockford, USA (1983),885–888.
3. Birr Chr.: Synthetic Small Thymic Peptides, an Immunregulatory Concept. Thymic Hormones & Lymphokines 1983 (A.?L. Goldstein, Ed.), Plenum Publ. Corp., Washington, D.C. (1984), 97–109.
4. Birr Chr., Bohn B. and Jaeger K.-H.: Biochemical Characterization and Immunomodulatory Action of Thymic Components as Determined by Flow Cytometry on Human Lymphocytes. Thymus 10, (1987), pp. 159–168.
5. Birr Chr., Nebe Th. and Becker G.: Site specific differentiation induction on T cells in vivo by synthetic thymic peptides to fight microbial infections and cancer. Immunotherapy of Infections (K.?N. Masishi, Ed.), Marcel Dekker, 1994.
6. Birr Chr., Nebe Th. and Becker G.: Synthetic Immunotherapeutic Peptide Drug Candidates. In: Peptides in Immunology (C. Schneider, Ed.), (1996), John Wiley & Sons, Ltd., 185–196.
7. Birr Chr., Braum G. Hirt W., Klett-Loch G.?H.: Statistic Combination of Thymus Peptides, a Synthetic Library Mimicing the Physiological Environment In: Peptides 1998 (S. Bajusz, F.?Hudecz, Eds.), Akademiai Kiado, Budapest, pp. 62–63 (1999).
8. Birr Chr.: Peptides — An Increasing Demand in Molecular Immunology. In: Innovation and Perspectives in Solid Phase Synthesis & Combinatorial Libraries (R. Epton, Ed.), Southhampton, England, UK, 2002, pp. 137–142. Mayflower Scientific Ltd., Kingswinfort,UK, (2003).
9. Birr Chr.: Development of a Bioassay for the Quality Control of the Drug Substance SCTL by Biological Means. Internal Report, 2005.
10. Cazzola P., Mazzanti P., Kouttab NM.: Update and future perspectives of a thymic biological response modifier (Thymomodulin). Immunopharmacol Immunotoxicol 9:195–216 (1987).
https://doi.org/10.3109/08923978709035210
11. Ciardelli T.?L., Incefy G.?S. and Birr Chr.: The Activity of Synthetic Thymosin-a1, C-terminal Peptides in the Azathioprine E-Rosette Inhibition Assay. Biochemistry 21, 4233–4237 (1982).
https://doi.org/10.1021/bi00261a008
12. Cunningham-Rundles S., Harbison M., Guirguis S., Valacer D., Chretien PB.: New perspectives on use of thymic factors in immune deficiency. Ann NY Acad Sci 730: 71–83 (1999).
https://doi.org/10.1111/j.1749-6632.1994.tb44240.x
13. Hirt W.: Bioaktivit?t — Statistisches Tetrapeptidgemisch SP/01/211096 (1996).
14. Ho A. D., Stehle B., Birr Chr., Heinzel W., Nebe?C. Th.: Differentiation Changes in Cord Blood T-Lymphocytes Induced by Synthetic C-Terminal Peptides of Thymosina1, Thymus 9, (1987) 77–84.
15. Leuschner J.: Acute skin irritation test (patch test) of SCTL (ORPEGEN) in rabbits. LPT Report No 102008/96 (from 1/13/1997).
16. Leuschner J.: Acute toxicity study of SCTL (ORPEGEN) by intravenous administration to Sprague-Dawley rats. LPT Report No 10207/96 (of 2/12/1997).
17. Leuschner J.: Mutagenicity study of SCTL (ORPEGEN) in the Salmonella typhimurium reverse mutation assay (in vitro). LPT Report No 10703/97 (of 9/12/1997).
18. L?pke N. P.: Zusammenfassender Bericht zur adjuvanten lokalen Anwendung von SCTL Pr?parationen bei Patienten unter zytostatischer Chemotherapie. Deutsche Zeitschrift f?r Onkologie 22: 13–20 (1990).
19. Maurer H. R.: Preclinical investigation of thymic preparations HTX and SCTL. Internal Investigational Report 2005.
20. NeuroBiotec: Investigations of skin irritation of SCTL as aqueous solutions (10%) using the EpiDerm® model MatTek Corporation, Ashland, USA, Internal Investigational Report 2005.
21. Schulof RS: Thymic peptide hormones: Basic properties and applications in cancer. CRC Crit. Rev. Oncol. Hematol 3:309–376 (1985).
https://doi.org/10.1016/S1040-8428(85)80035-4